<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35745708</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary <i>sequelae</i> after COVID-19 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics14061135</ELocationID><Abstract><AbstractText>Post-COVID syndrome or <i>long COVID</i> is defined as the persistence of symptoms after confirmed SARS-CoV-2 infection, the pathogen responsible for coronavirus disease. The content herein presented reviews the reported long-term consequences and aftereffects of COVID-19 infection and the potential strategies to adopt for their management. Recent studies have shown that severe forms of COVID-19 can progress into acute respiratory distress syndrome (ARDS), a predisposing factor of pulmonary fibrosis that can irreversibly compromise respiratory function. Considering that the most serious complications are observed in the airways, the inhalation delivery of drugs directly to the lungs should be preferred, since it allows to lower the dose and systemic side effects. Although further studies are needed to optimize these techniques, recent studies have also shown the importance of in vitro models to recreate the SARS-CoV-2 infection and study its sequelae. The information reported suggests the necessity to develop new inhalation therapies in order to improve the quality of life of patients who suffer from this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD Program in Drug Discovery and Development, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aquino</LastName><ForeName>Rita P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Gaudio</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3852-4523</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campiglia</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1069-2181</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4362-4388</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">in vitro lung models</Keyword><Keyword MajorTopicYN="N">inhalation therapy</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID fibrosis</Keyword><Keyword MajorTopicYN="N">post-COVID sequelae</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35745708</ArticleId><ArticleId IdType="pmc">PMC9229559</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics14061135</ArticleId><ArticleId IdType="pii">pharmaceutics14061135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yan Z., Yang M., Lai C.-L. Long COVID-19 syndrome: A comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans. Biomedicines. 2021;9:966. doi: 10.3390/biomedicines9080966.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080966</ArticleId><ArticleId IdType="pmc">PMC8394513</ArticleId><ArticleId IdType="pubmed">34440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang D.H., McCoy R.G. Planning for the post-COVID syndrome: How payers can mitigate long-term complications of the pandemic. J. Gen. Intern. Med. 2020;35:3036&#x2013;3039. doi: 10.1007/s11606-020-06042-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-06042-3</ArticleId><ArticleId IdType="pmc">PMC7375754</ArticleId><ArticleId IdType="pubmed">32700223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett M.L., Glozier N.S., Martiniuk A.L., Jan S., Anderson C.S. Sydney Epilepsy Incidence Study to Measure Illness Consequences: The SESIMIC Observational Epilepsy Study Protocol. BMC Neurol. 2011;11:3. doi: 10.1186/1471-2377-11-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-11-3</ArticleId><ArticleId IdType="pmc">PMC3025848</ArticleId><ArticleId IdType="pubmed">21214957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H., Patel K., Greenwood D., Halpin S., Lewthwaite P., Salawu A., Eyre L., Breen A., O&#x2019;Connor R., Jones A., et al. Long-Term Clinical Outcomes in Survivors of Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome Coronavirus Outbreaks after Hospitalisation or ICU Admission: A Systematic Review and Meta-Analysis. J. Rehabil. Med. 2020;52:jrm00063. doi: 10.2340/16501977-2694.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-2694</ArticleId><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui D.S. Impact of Severe Acute Respiratory Syndrome (SARS) on Pulmonary Function, Functional Capacity and Quality of Life in a Cohort of Survivors. Thorax. 2005;60:401&#x2013;409. doi: 10.1136/thx.2004.030205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.2004.030205</ArticleId><ArticleId IdType="pmc">PMC1758905</ArticleId><ArticleId IdType="pubmed">15860716</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty S.E., Guo Y., Heath K., Dasmari&#xf1;as M.C., Jubilo K.G., Samranvedhya J., Lipsitch M., Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: Retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M., Maralakunte M., Garg S., Dhooria S., Sehgal I., Bhalla A.S., Vijayvergiya R., Grover S., Bhatia V., Jagia P., et al. The conundrum of &#x2018;Long-COVID-19&#x2019;: A narrative review. IJGM. 2021;14:2491&#x2013;2506. doi: 10.2147/IJGM.S316708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalski J.E., Kurche J.S., Schwartz D.A. From ARDS to pulmonary fibrosis: The next phase of the COVID-19 pandemic? Transl. Res. 2022;241:13&#x2013;24. doi: 10.1016/j.trsl.2021.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.09.001</ArticleId><ArticleId IdType="pmc">PMC8452088</ArticleId><ArticleId IdType="pubmed">34547499</ArticleId></ArticleIdList></Reference><Reference><Citation>Udwadia Z., Koul P., Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021;38:41. doi: 10.4103/lungindia.lungindia_818_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/lungindia.lungindia_818_20</ArticleId><ArticleId IdType="pmc">PMC8104338</ArticleId><ArticleId IdType="pubmed">33686978</ArticleId></ArticleIdList></Reference><Reference><Citation>Boechat J.L., Chora I., Morais A., Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology&#x2014;Current perspectives. Pulmonology. 2021;27:423&#x2013;437. doi: 10.1016/j.pulmoe.2021.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2021.03.008</ArticleId><ArticleId IdType="pmc">PMC8040543</ArticleId><ArticleId IdType="pubmed">33867315</ArticleId></ArticleIdList></Reference><Reference><Citation>Eedara B.B., Alabsi W., Encinas-Basurto D., Polt R., Ledford J.G., Mansour H.M. Inhalation delivery for the treatment and prevention of COVID-19 infection. Pharmaceutics. 2021;13:1077. doi: 10.3390/pharmaceutics13071077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13071077</ArticleId><ArticleId IdType="pmc">PMC8308954</ArticleId><ArticleId IdType="pubmed">34371768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta Pasini A.M., Stranieri C., Cominacini L., Mozzini C. Potential role of antioxidant and anti-inflammatory therapies to prevent severe SARS-CoV-2 complications. Antioxidants. 2021;10:272. doi: 10.3390/antiox10020272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10020272</ArticleId><ArticleId IdType="pmc">PMC7916604</ArticleId><ArticleId IdType="pubmed">33578849</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F., Veronesi F., Martini L., Landini M.P., Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-Viral Stage of the Disease. A Systematic Review of the Current Data. Front. Med. 2021;8:653516. doi: 10.3389/fmed.2021.653516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.653516</ArticleId><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivashanmugam K., Kandasamy M., Subbiah R., Ravikumar V. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-&#x3b2; signalling in COVID-19 survivors. Life Sci. 2021;266:118883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831549</ArticleId><ArticleId IdType="pubmed">33316266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R.M.M., Ghonimy M.B.I. Post-COVID-19 pneumonia lung fibrosis: A worrisome sequelae in surviving patients. Egypt. J. Radiol. Nucl. Med. 2021;52:101. doi: 10.1186/s43055-021-00484-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00484-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutchmansingh D.D., Knauert M.P., Antin-Ozerkis D.E., Chupp G., Cohn L., Dela Cruz C.S., Ferrante L.E., Herzog E.L., Koff J., Rochester C.L., et al. A clinic blueprint for post-coronavirus disease 2019 RECOVERY. Chest. 2021;159:949&#x2013;958. doi: 10.1016/j.chest.2020.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.10.067</ArticleId><ArticleId IdType="pmc">PMC7641526</ArticleId><ArticleId IdType="pubmed">33159907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological Sequelae of Long-Haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezkalla S.H., Kloner R.A. Post-acute sequelae of SARS-COVID-2 syndrome: Just the beginning. Cardiol Res. 2021;12:279&#x2013;285. doi: 10.14740/cr1290.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1290</ArticleId><ArticleId IdType="pmc">PMC8510656</ArticleId><ArticleId IdType="pubmed">34691325</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yo E.C., Kadharusman M.M., Karman A.P., Louisa M., Arozal W. Potential pharmacological options and new avenues using inhaled curcumin nanoformulations for treatment of post-COVID-19 fibrosis. Syst. Rev. Pharm. 2021;12:1119&#x2013;1128.</Citation></Reference><Reference><Citation>Banu N., Panikar S.S., Leal L.R., Leal A.R. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: Therapeutic implications. Life Sci. 2020;256:117905. doi: 10.1016/j.lfs.2020.117905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117905</ArticleId><ArticleId IdType="pmc">PMC7832382</ArticleId><ArticleId IdType="pubmed">32504757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy S., Subbian S. Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis. Clin. Microbiol. Rev. 2021;34:e00299-20. doi: 10.1128/CMR.00299-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00299-20</ArticleId><ArticleId IdType="pmc">PMC8142516</ArticleId><ArticleId IdType="pubmed">33980688</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39:529&#x2013;539. doi: 10.1007/s00281-017-0629-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson B.T., Chambers R.C., Liu K.D. Acute Respiratory Distress Syndrome. N. Engl. J. Med. 2017;377:562&#x2013;572. doi: 10.1056/NEJMra1608077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1608077</ArticleId><ArticleId IdType="pubmed">28792873</ArticleId></ArticleIdList></Reference><Reference><Citation>Suess C., Hausmann R. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation. Int. J. Leg. Med. 2020;134:1285&#x2013;1290. doi: 10.1007/s00414-020-02319-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00414-020-02319-8</ArticleId><ArticleId IdType="pmc">PMC7273129</ArticleId><ArticleId IdType="pubmed">32504146</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Larson C., Hammond T.C., Oronsky A., Kesari S., Lybeck M., Reid T.R. A review of persistent post-COVID syndrome (PPCS) Clin. Rev. Allergy Immunol. 2021:1&#x2013;9. doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Plataki M., Hubmayr R.D. The physical basis of ventilator-induced lung injury. Expert Rev. Respir. Med. 2010;4:373&#x2013;385. doi: 10.1586/ers.10.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ers.10.28</ArticleId><ArticleId IdType="pmc">PMC2904955</ArticleId><ArticleId IdType="pubmed">20524920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Benitez N.E., Laffey J.G., Parotto M., Spieth P.M., Villar J., Zhang H., Slutsky A.S. Mechanical ventilation&#x2013;associated lung fibrosis in acute respiratory distress syndrome. Anesthesiology. 2014;121:189&#x2013;198. doi: 10.1097/ALN.0000000000000264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000000264</ArticleId><ArticleId IdType="pmc">PMC4991945</ArticleId><ArticleId IdType="pubmed">24732023</ArticleId></ArticleIdList></Reference><Reference><Citation>Abodonya A.M., Abdelbasset W.K., Awad E.A., Elalfy I.E., Salem H.A., Elsayed S.H. Inspiratory muscle training for recovered COVID-19 patients after weaning from mechanical ventilation: A pilot control clinical study. Medicine. 2021;100:e25339. doi: 10.1097/MD.0000000000025339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000025339</ArticleId><ArticleId IdType="pmc">PMC8021337</ArticleId><ArticleId IdType="pubmed">33787632</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura Y., Mitsuyama Y., Minami K., Nishida T., Watanabe A., Okada N., Yamakawa K., Nochioka K., Fujimi S. Efficacy and safety of Nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int. J. Infect. Dis. 2021;108:454&#x2013;460. doi: 10.1016/j.ijid.2021.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.05.055</ArticleId><ArticleId IdType="pmc">PMC8146615</ArticleId><ArticleId IdType="pubmed">34048887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Kream R.M., Stefano G.B. Long-term respiratory and neurological sequelae of COVID-19. Med. Sci. Monit. 2020;26:e928996-1&#x2013;e928996-10. doi: 10.12659/MSM.928996.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Esenda&#x11f;li D., Yilmaz A., Ak&#xe7;ay &#x15e;., &#xd6;zl&#xfc; T. Post-COVID syndrome: Pulmonary complications. Turk. J. Med. Sci. 2021;51:3359&#x2013;3371. doi: 10.3906/sag-2106-238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-2106-238</ArticleId><ArticleId IdType="pmc">PMC8771021</ArticleId><ArticleId IdType="pubmed">34284532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.-C., Ng A.W.-K., Lee L.S.-U., Kaw G., Kwek S.-K., Leow M.K.-S., Earnest A. 1-Year Pulmonary Function and Health Status in Survivors of Severe Acute Respiratory Syndrome. Chest. 2005;128:1393&#x2013;1400. doi: 10.1378/chest.128.3.1393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.128.3.1393</ArticleId><ArticleId IdType="pmc">PMC7094739</ArticleId><ArticleId IdType="pubmed">16162734</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Castro R., Vasconcello-Castillo L., Alsina-Restoy X., Solis-Navarro L., Burgos F., Puppo H., Vilar&#xf3; J. Respiratory Function in Patients Post-Infection by COVID-19: A Systematic Review and Meta-Analysis. Pulmonology. 2021;27:328&#x2013;337. doi: 10.1016/j.pulmoe.2020.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pulmoe.2020.10.013</ArticleId><ArticleId IdType="pmc">PMC7687368</ArticleId><ArticleId IdType="pubmed">33262076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerardo A.M., Almeida T., Maduro S., Carvalho M., Bol&#xe9;o-Tom&#xe9; J.P., Liberato H. Pulmonary function, functional capacity and health status in COVID-19 survivors. Rev. Med. Cl&#xed;nica. 2021;5:e11052105023.</Citation></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritas S.K. Mast Cells Contribute to Coronavirus-Induced Inflammation: New Anti-Inflammatory Strategy. J. Biol. Regul. Homeost. Agents. 2020;34:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32013309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezi B., Chan L., Knapp J.P., Karimi N., Alizadeh K., Mehrani Y., Bridle B.W., Karimi K. Cytokine storm syndrome in SARS-CoV-2 infections: A functional role of mast cells. Cells. 2021;10:1761. doi: 10.3390/cells10071761.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071761</ArticleId><ArticleId IdType="pmc">PMC8308097</ArticleId><ArticleId IdType="pubmed">34359931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Stabilizing mast cells by commonly used drugs: A novel therapeutic target to relieve post-COVID syndrome? Drug Discov. Ther. 2020;14:259&#x2013;261. doi: 10.5582/ddt.2020.03095.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2020.03095</ArticleId><ArticleId IdType="pubmed">33116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilin&#xe7; E., Barano&#x11f;lu Y. Mast Cell Stabilizers as a Supportive Therapy Can Contribute to Alleviate Fatal Inflammatory Responses and Severity of Pulmonary Complications in COVID-19 Infection. Anadolu Klin. T&#x131;p Bilimleri Derg. 2020;25:111&#x2013;118. doi: 10.21673/anadoluklin.720116.</Citation><ArticleIdList><ArticleId IdType="doi">10.21673/anadoluklin.720116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakavas S., Karayiannis D., Mastora Z. The Complex Interplay between Immunonutrition, Mast Cells, and Histamine Signaling in COVID-19. Nutrients. 2021;13:3458. doi: 10.3390/nu13103458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13103458</ArticleId><ArticleId IdType="pmc">PMC8537261</ArticleId><ArticleId IdType="pubmed">34684460</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba A., Tachi M., Maruyama Y., Kazama I. Olopatadine Inhibits Exocytosis in Rat Peritoneal Mast Cells by Counteracting Membrane Surface Deformation. Cell. Physiol. Biochem. 2015;35:386&#x2013;396. doi: 10.1159/000369704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369704</ArticleId><ArticleId IdType="pubmed">25591779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I., Saito K., Baba A., Mori T., Abe N., Endo Y., Toyama H., Ejima Y., Matsubara M., Yamauchi M. Clarithromycin Dose-Dependently Stabilizes Rat Peritoneal Mast Cells. Chemotherapy. 2016;61:295&#x2013;303. doi: 10.1159/000445023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445023</ArticleId><ArticleId IdType="pubmed">27088971</ArticleId></ArticleIdList></Reference><Reference><Citation>Manniello M.D., Del Gaudio P., Aquino R.P., Russo P. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility. Int. J. Pharm. 2017;533:463&#x2013;469. doi: 10.1016/j.ijpharm.2017.03.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2017.03.079</ArticleId><ArticleId IdType="pubmed">28377314</ArticleId></ArticleIdList></Reference><Reference><Citation>Manniello M.D., Del Gaudio P., Porta A., Aquino R.P., Russo P. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. Eur. J. Pharm. Biopharm. 2016;104:1&#x2013;6. doi: 10.1016/j.ejpb.2016.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2016.04.009</ArticleId><ArticleId IdType="pubmed">27106605</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano E.J., Fonseca Fuentes X., Corsini Campioli C., O&#x2019;Horo J.C., Abu Saleh O., Odeyemi Y., Yadav H., Temesgen Z. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes. Chest. 2021;159:1019&#x2013;1040. doi: 10.1016/j.chest.2020.10.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.10.054</ArticleId><ArticleId IdType="pmc">PMC7598533</ArticleId><ArticleId IdType="pubmed">33129791</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesel M., Wagner C., Mikolajewska A., Stegemann M., Fichtner F., Metzendorf M.-I., Nair A.A., Daniel J., Fischer A.-L., Skoetz N. Inhaled Corticosteroids for the Treatment of COVID-19. Cochrane Database Syst. Rev. 2022;3:1&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905579</ArticleId><ArticleId IdType="pubmed">35262185</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne S., Li X., Yang C.X., Leitao Filho F.S., Hern&#xe1;ndez Cordero A.I., Yang C.W.T., Shaipanich T., van Eeden S.F., Leung J.M., Lam S., et al. Inhaled Corticosteroids Downregulate SARS-CoV-2-Related Genes in COPD: Results from a Randomised Controlled Trial. Eur. Respir. J. 2021;58:2100130. doi: 10.1183/13993003.00130-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00130-2021</ArticleId><ArticleId IdType="pmc">PMC8015643</ArticleId><ArticleId IdType="pubmed">33795322</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruta H., He H. PAK1-Blockers: Potential Therapeutics against COVID-19. Med. Drug Discov. 2020;6:100039. doi: 10.1016/j.medidd.2020.100039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2020.100039</ArticleId><ArticleId IdType="pmc">PMC7166201</ArticleId><ArticleId IdType="pubmed">32313880</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemency B.M., Varughese R., Gonzalez-Rojas Y., Morse C.G., Phipatanakul W., Koster D.J., Blaiss M.S. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults with Symptomatic COVID-19: A Randomized Clinical Trial. JAMA Intern. Med. 2022;182:42. doi: 10.1001/jamainternmed.2021.6759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6759</ArticleId><ArticleId IdType="pmc">PMC8609464</ArticleId><ArticleId IdType="pubmed">34807241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripa M., Galli L., Poli A., Oltolini C., Spagnuolo V., Mastrangelo A., Muccini C., Monti G., De Luca G., Landoni G., et al. Secondary infections in patients hospitalized with COVID-19: Incidence and predictive factors. Clin. Microbiol. Infect. 2021;27:451&#x2013;457. doi: 10.1016/j.cmi.2020.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.10.021</ArticleId><ArticleId IdType="pmc">PMC7584496</ArticleId><ArticleId IdType="pubmed">33223114</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., Soucy J.-P.R., Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020;26:1622&#x2013;1629. doi: 10.1016/j.cmi.2020.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.016</ArticleId><ArticleId IdType="pmc">PMC7832079</ArticleId><ArticleId IdType="pubmed">32711058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama Amin B.J., Kakamad F.H., Ahmed G.S., Ahmed S.F., Abdulla B.A., mohammed S.H., Mikael T.M., Salih R.Q., Ali R.K., Salh A.M., et al. Post COVID-19 Pulmonary Fibrosis; a Meta-Analysis Study. Ann. Med. Surg. 2022;77:103590. doi: 10.1016/j.amsu.2022.103590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103590</ArticleId><ArticleId IdType="pmc">PMC8983072</ArticleId><ArticleId IdType="pubmed">35411216</ArticleId></ArticleIdList></Reference><Reference><Citation>Echeverr&#xed;a-Esnal D., Martin-Ontiyuelo C., Navarrete-Rouco M.E., De-Antonio Cusc&#xf3; M., Ferr&#xe1;ndez O., Horcajada J.P., Grau S. Azithromycin in the Treatment of COVID-19: A Review. Expert Rev. Anti Infect. Ther. 2021;19:147&#x2013;163. doi: 10.1080/14787210.2020.1813024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1813024</ArticleId><ArticleId IdType="pubmed">32853038</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Richeldi L. Current Approaches to the Management of Idiopathic Pulmonary Fibrosis. Respir. Med. 2017;129:24&#x2013;30. doi: 10.1016/j.rmed.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2017.05.017</ArticleId><ArticleId IdType="pubmed">28732832</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaritopoulos G.A., Vasarmidi E., Antoniou K.M. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: An evidence-based review of its place in therapy. Core Evid. 2016;11:11&#x2013;22. doi: 10.2147/CE.S76549.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CE.S76549</ArticleId><ArticleId IdType="pmc">PMC4936814</ArticleId><ArticleId IdType="pubmed">27445644</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Togo S., Kadoya K., Tulafu M., Namba Y., Iwai M., Watanabe J., Nagahama K., Okabe T., Hidayat M., et al. Pirfenidone Attenuates Lung Fibrotic Fibroblast Responses to Transforming Growth Factor-&#x392;1. Respir. Res. 2019;20:119. doi: 10.1186/s12931-019-1093-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-019-1093-z</ArticleId><ArticleId IdType="pmc">PMC6558902</ArticleId><ArticleId IdType="pubmed">31185973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Wei Y., He L., Zhang H., Hu Q., Yue H., He J., Dai H. A Trial of Pirfenidone in Hospitalized Adult Patients with Severe Coronavirus Disease 2019. Chin. Med. J. 2022;135:368&#x2013;370. doi: 10.1097/CM9.0000000000001614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001614</ArticleId><ArticleId IdType="pmc">PMC8812696</ArticleId><ArticleId IdType="pubmed">34855641</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Ying Y. The inhibitory effect of curcumin on virus-induced cytokine storm and its potential use in the associated severe pneumonia. Front. Cell Dev. Biol. 2020;8:479. doi: 10.3389/fcell.2020.00479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00479</ArticleId><ArticleId IdType="pmc">PMC7303286</ArticleId><ArticleId IdType="pubmed">32596244</ArticleId></ArticleIdList></Reference><Reference><Citation>Memorial Sloan Kettering Cancer Center Phase II Study of N-Acetylcysteine in Severe or Critically Ill Patients with Refractory COVID-19 Infection.  [(accessed on 18 May 2022)];2021  Available online:  clinicaltrials.gov.</Citation></Reference><Reference><Citation>Horowitz R.I., Freeman P.R., Bruzzese J. Efficacy of Glutathione Therapy in Relieving Dyspnea Associated with COVID-19 Pneumonia: A Report of 2 Cases. Respir. Med. Case Rep. 2020;30:101063. doi: 10.1016/j.rmcr.2020.101063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2020.101063</ArticleId><ArticleId IdType="pmc">PMC7172740</ArticleId><ArticleId IdType="pubmed">32322478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitiello A., Troiano V., La Porta R. What will be the role of molnupiravir in the treatment of COVID-19 infection? Drugs Perspect. 2021;37:579&#x2013;580. doi: 10.1007/s40267-021-00879-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40267-021-00879-2</ArticleId><ArticleId IdType="pmc">PMC8570236</ArticleId><ArticleId IdType="pubmed">34754175</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnupiravir and Remdesivir Available for the Treatment of Non-Hospitalized COVID-19 Patients at High Risk of Progressing to Severe Disease.  [(accessed on 19 May 2022)]; Available online:  https://www.aifa.gov.it/en/-/disponibilit%C3%A0-molnupiravir-e-remdesivir-trattamento-pazienti-non-ospedalizzati-covid-19-1.</Citation></Reference><Reference><Citation>Mitrani M.I., Bellio M.A., Meglin A., Khan A., Xu X., Haskell G., Arango A., Shapiro G.C. Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic. Respir. Med. Case Rep. 2021;34:101502. doi: 10.1016/j.rmcr.2021.101502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2021.101502</ArticleId><ArticleId IdType="pmc">PMC8405236</ArticleId><ArticleId IdType="pubmed">34485048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrani M.I., Bellio M.A., Sagel A., Saylor M., Kapp W., VanOsdol K., Haskell G., Stewart D., Abdullah Z., Santos I., et al. Case report: Administration of amniotic fluid-derived nanoparticles in three severely Ill COVID-19 patients. Front. Med. 2021;8:242. doi: 10.3389/fmed.2021.583842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.583842</ArticleId><ArticleId IdType="pmc">PMC8010176</ArticleId><ArticleId IdType="pubmed">33816515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ampio Pharmaceuticals Receives Investigational Review Board Approval for Its Phase I Long COVID-19 Trial (AP-018)  [(accessed on 19 May 2022)].  Available online:  https://www.biospace.com/article/ampio-pharmaceuticals-receives-investigational-review-board-approval-for-its-phase-i-long-covid-19-trial-ap-018-/</Citation></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; What we know so far. Front. Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdellatif A.A.H., Tawfeek H.M., Abdelfattah A., El-Saber Batiha G., Hetta H.F. Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems. J. Drug Deliv. Sci. Technol. 2021;63:102435. doi: 10.1016/j.jddst.2021.102435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2021.102435</ArticleId><ArticleId IdType="pmc">PMC7894098</ArticleId><ArticleId IdType="pubmed">33643448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechowicz K., Dro&#x17c;d&#x17c;al S., Machaj F., Rosik J., Szostak B., Zegan-Bara&#x144;ska M., Biernawska J., Dabrowski W., Rotter I., Kotfis K. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. JCM. 2020;9:1917. doi: 10.3390/jcm9061917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061917</ArticleId><ArticleId IdType="pmc">PMC7356800</ArticleId><ArticleId IdType="pubmed">32575380</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman S.P. Drug delivery to the lungs: Challenges and opportunities. Ther. Deliv. 2017;8:647&#x2013;661. doi: 10.4155/tde-2017-0037.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde-2017-0037</ArticleId><ArticleId IdType="pubmed">28730933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright J. Inhaler Devices for the Treatment of Asthma and Chronic Obstructive Airways Disease (COPD) Qual. Saf. Health Care. 2002;11:376&#x2013;382. doi: 10.1136/qhc.11.4.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/qhc.11.4.376</ArticleId><ArticleId IdType="pmc">PMC1758018</ArticleId><ArticleId IdType="pubmed">12468702</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorley A.J., Tetley T.D. New Perspectives in Nanomedicine. Pharmacol. Ther. 2013;140:176&#x2013;185. doi: 10.1016/j.pharmthera.2013.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.06.008</ArticleId><ArticleId IdType="pubmed">23811125</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud A., Discher D.E. Lung Vascular Targeting through Inhalation Delivery: Insight from Filamentous Viruses and Other Shapes. IUBMB Life. 2011;63:607&#x2013;612. doi: 10.1002/iub.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.481</ArticleId><ArticleId IdType="pubmed">21721102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for Drug Delivery to the Lungs. Trends Biotechnol. 2007;25:563&#x2013;570. doi: 10.1016/j.tibtech.2007.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2007.09.005</ArticleId><ArticleId IdType="pubmed">17997181</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain J.D., Knudson D.E., Sorokin S.P., Davis M.A. Pulmonary Distribution of Particles given by Intratracheal Instillation or by Aerosol Inhalation. Environ. Res. 1976;11:13&#x2013;33. doi: 10.1016/0013-9351(76)90107-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0013-9351(76)90107-9</ArticleId><ArticleId IdType="pubmed">1253768</ArticleId></ArticleIdList></Reference><Reference><Citation>Groneberg D.A., Witt C., Wagner U., Chung K.F., Fischer A. Fundamentals of Pulmonary Drug Delivery. Respir. Med. 2003;97:382&#x2013;387. doi: 10.1053/rmed.2002.1457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/rmed.2002.1457</ArticleId><ArticleId IdType="pubmed">12693798</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghardt J.M., Kloft C., Sharma A. Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. Can. Respir. J. 2018;2018:2732017. doi: 10.1155/2018/2732017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2732017</ArticleId><ArticleId IdType="pmc">PMC6029458</ArticleId><ArticleId IdType="pubmed">30018677</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo P., Alhaique F., Caramella C., Conti B., Gazzaniga A., Vidale E. Principi di Tecnologia Farmaceutica. 2nd ed. Ambrosiana; Milano, Italy: 2015.</Citation></Reference><Reference><Citation>Labiris N.R., Dolovich M.B. Pulmonary Drug Delivery. Part I: Physiological Factors Affecting Therapeutic Effectiveness of Aerosolized Medications: Physiological Factors Affecting the Effectiveness of Inhaled Drugs. Br. J. Clin. Pharmacol. 2003;56:588&#x2013;599. doi: 10.1046/j.1365-2125.2003.01892.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2003.01892.x</ArticleId><ArticleId IdType="pmc">PMC1884307</ArticleId><ArticleId IdType="pubmed">14616418</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman S. Improving Inhaler Technique, Adherence to Therapy and the Precision of Dosing: Major Challenges for Pulmonary Drug Delivery. Expert Opin. Drug Deliv. 2014;11:365&#x2013;378. doi: 10.1517/17425247.2014.873402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2014.873402</ArticleId><ArticleId IdType="pubmed">24386924</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan C., Barry P.W. The Science of Nebulised Drug Delivery. Thorax. 1997;52:S31&#x2013;S44. doi: 10.1136/thx.52.suppl_2.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.52.suppl_2.31</ArticleId><ArticleId IdType="pmc">PMC1765865</ArticleId><ArticleId IdType="pubmed">9155849</ArticleId></ArticleIdList></Reference><Reference><Citation>Sou T., Bergstr&#xf6;m C.A.S. Contemporary Formulation Development for Inhaled Pharmaceuticals. J. Pharm. Sci. 2021;110:66&#x2013;86. doi: 10.1016/j.xphs.2020.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.09.006</ArticleId><ArticleId IdType="pubmed">32916138</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilcer G., Amighi K. Formulation Strategy and Use of Excipients in Pulmonary Drug Delivery. Int. J. Pharm. 2010;392:1&#x2013;19. doi: 10.1016/j.ijpharm.2010.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.03.017</ArticleId><ArticleId IdType="pubmed">20223286</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin B.K., Fink J.B. Optimizing Aerosol Delivery by Pressurized Metered-Dose Inhalers. Respir. Care. 2005;50:1191&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink J.B. Metered-dose inhalers, dry powder inhalers, and transitions. Respir. Care. 2000;45:623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahookhosh K., Saidi M., Mohammadpourfard M., Aminfar H., Hamishehkar H., Farnoud A., Schmid O. Flow Structure and Particle Deposition Analyses for Optimization of a Pressurized Metered Dose Inhaler (PMDI) in a Model of Tracheobronchial Airway. Eur. J. Pharm. Sci. 2021;164:105911. doi: 10.1016/j.ejps.2021.105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2021.105911</ArticleId><ArticleId IdType="pubmed">34129919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandel A., Goyal A.K., Ghosh G., Rath G. Recent Advances in Aerosolised Drug Delivery. Biomed. Pharmacother. 2019;112:108601. doi: 10.1016/j.biopha.2019.108601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.108601</ArticleId><ArticleId IdType="pubmed">30780107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yawn B., Colice G. Practical Aspects of Inhaler Use in the Management of Chronic Obstructive Pulmonary Disease in the Primary Care Setting. COPD. 2012;7:495. doi: 10.2147/COPD.S32674.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S32674</ArticleId><ArticleId IdType="pmc">PMC3413176</ArticleId><ArticleId IdType="pubmed">22888221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothirat C., Chaiwong W., Phetsuk N., Pisalthanapuna S., Chetsadaphan N., Choomuang W. Evaluating Inhaler Use Technique in COPD Patients. COPD. 2015;10:1291. doi: 10.2147/COPD.S85681.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S85681</ArticleId><ArticleId IdType="pmc">PMC4501446</ArticleId><ArticleId IdType="pubmed">26185435</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beerendonk I., Mesters I., Mudde A.N., Tan T.D. Assessment of the Inhalation Technique in Outpatients with Asthma or Chronic Obstructive Pulmonary Disease Using a Metered-Dose Inhaler or Dry Powder Device. J. Asthma. 1998;35:273&#x2013;279. doi: 10.3109/02770909809068218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02770909809068218</ArticleId><ArticleId IdType="pubmed">9661680</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza V., Giner J., Rodrigo G.J., Dolovich M.B., Sanchis J. Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review. J. Allergy Clin. Immunol. Pract. 2018;6:987&#x2013;995. doi: 10.1016/j.jaip.2017.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2017.12.032</ArticleId><ArticleId IdType="pubmed">29355645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavorini F., Magnan A., Christophe Dubus J., Voshaar T., Corbetta L., Broeders M., Dekhuijzen R., Sanchis J., Viejo J.L., Barnes P., et al. Effect of Incorrect Use of Dry Powder Inhalers on Management of Patients with Asthma and COPD. Respir. Med. 2008;102:593&#x2013;604. doi: 10.1016/j.rmed.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2007.11.003</ArticleId><ArticleId IdType="pubmed">18083019</ArticleId></ArticleIdList></Reference><Reference><Citation>Telko M.J., Hickey A.J. Dry Powder Inhaler Formulation. Respir. Care. 2005;50:1209&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P. Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems. J. Drug Deliv. 2016;2016:8290963. doi: 10.1155/2016/8290963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/8290963</ArticleId><ArticleId IdType="pmc">PMC5102732</ArticleId><ArticleId IdType="pubmed">27867663</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam N., Gladki E. Dry Powder Inhalers (DPIs)&#x2014;A Review of Device Reliability and Innovation. Int. J. Pharm. 2008;360:1&#x2013;11. doi: 10.1016/j.ijpharm.2008.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2008.04.044</ArticleId><ArticleId IdType="pubmed">18583072</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A., Battle K., Lurslurchachai L., Halm E.A., Wisnivesky J.P. Inhaler Device, Administration Technique, and Adherence to Inhaled Corticosteroids in Patients with Asthma. Prim. Care Respir. J. 2011;20:148&#x2013;154. doi: 10.4104/pcrj.2011.00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.4104/pcrj.2011.00022</ArticleId><ArticleId IdType="pmc">PMC6549817</ArticleId><ArticleId IdType="pubmed">21437565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumby B., Slater A., Atkins P.J., Prime D. Review of dry powder inhalers. Adv. Drug Deliv. Rev. 1997;26:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837532</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughney J., Price D., Barnes N.C., Virchow J.C., Roche N., Chrystyn H. Choosing Inhaler Devices for People with Asthma: Current Knowledge and Outstanding Research Needs. Respir. Med. 2010;104:1237&#x2013;1245. doi: 10.1016/j.rmed.2010.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2010.04.012</ArticleId><ArticleId IdType="pubmed">20472415</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinen N., Kl&#xf6;hn M., Steinmann E., Pfaender S. In vitro lung models and their application to study SARS-CoV-2 pathogenesis and disease. Viruses. 2021;13:792. doi: 10.3390/v13050792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050792</ArticleId><ArticleId IdType="pmc">PMC8144959</ArticleId><ArticleId IdType="pubmed">33925255</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfoori A., Amereh M., Dabiri S.M.H., Askari E., Walsh T., Akbari M. The role of biomaterials and three dimensional (3D) in Vitro tissue models in fighting against COVID-19. Biomater. Sci. 2021;9:1217&#x2013;1226. doi: 10.1039/D0BM01616K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0BM01616K</ArticleId><ArticleId IdType="pubmed">33355542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins R.G., Moore B.B., Chambers R.C., Eickelberg O., K&#xf6;nigshoff M., Kolb M., Laurent G.J., Nanthakumar C.B., Olman M.A., Pardo A., et al. An official american thoracic society workshop report: Use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2017;56:667&#x2013;679. doi: 10.1165/rcmb.2017-0096ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2017-0096ST</ArticleId><ArticleId IdType="pmc">PMC5800895</ArticleId><ArticleId IdType="pubmed">28459387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener M., Roldan N., Machahua C., Sengupta A., Geiser T., Guenat O.T., Funke-Chambour M., Hobi N., Kruithof-de Julio M. Human-based advanced in vitro approaches to investigate lung fibrosis and pulmonary effects of COVID-19. Front. Med. 2021;8:555. doi: 10.3389/fmed.2021.644678.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.644678</ArticleId><ArticleId IdType="pmc">PMC8139419</ArticleId><ArticleId IdType="pubmed">34026781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerckens M., Alsafadi H.N., Wagner D.E., Lindner M., Burgstaller G., K&#xf6;nigshoff M. Generation of human 3D lung tissue cultures (3D-LTCs) for disease modeling. JoVE. 2019;144:58437. doi: 10.3791/58437.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/58437</ArticleId><ArticleId IdType="pubmed">30829341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundarakrishnan A., Chen Y., Black L.D., Aldridge B.B., Kaplan D.L. Engineered cell and tissue models of pulmonary fibrosis. Adv. Drug Deliv. Rev. 2018;129:78&#x2013;94. doi: 10.1016/j.addr.2017.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2017.12.013</ArticleId><ArticleId IdType="pubmed">29269274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., Betts C., Cunoosamy D.M., &#xc5;berg P.M., Hornberg J.J., Sivars K.B., Cohen T.S. Use of precision cut lung slices as a translational model for the study of lung biology. Respir. Res. 2019;20:162. doi: 10.1186/s12931-019-1131-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-019-1131-x</ArticleId><ArticleId IdType="pmc">PMC6642541</ArticleId><ArticleId IdType="pubmed">31324219</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui K.P.Y., Cheung M.-C., Perera R.A.P.M., Ng K.-C., Bui C.H.T., Ho J.C.W., Ng M.M.T., Kuok D.I.T., Shih K.C., Tsao S.-W., et al. Tropism, Replication Competence, and Innate Immune Responses of the Coronavirus SARS-CoV-2 in Human Respiratory Tract and Conjunctiva: An Analysis in Ex-Vivo and In-Vitro Cultures. Lancet Respir. Med. 2020;8:687&#x2013;695. doi: 10.1016/S2213-2600(20)30193-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30193-4</ArticleId><ArticleId IdType="pmc">PMC7252187</ArticleId><ArticleId IdType="pubmed">32386571</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C. Human lung slices: New uses for an old model. Am. J. Respir. Cell Mol. Biol. 2021;65:471&#x2013;472. doi: 10.1165/rcmb.2021-0268ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0268ED</ArticleId><ArticleId IdType="pmc">PMC8641856</ArticleId><ArticleId IdType="pubmed">34348085</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Krishnamoorthy N., Patel K.R., Rosas I., Sanderson M.J., Ai X. Cryopreserved human precision-cut lung slices as a bioassay for live tissue banking. A viability study of bronchodilation with bitter-taste receptor agonists. Am. J. Respir. Cell Mol. Biol. 2016;54:656&#x2013;663. doi: 10.1165/rcmb.2015-0290MA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2015-0290MA</ArticleId><ArticleId IdType="pmc">PMC4942196</ArticleId><ArticleId IdType="pubmed">26550921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A.M., Hoffman T., Luu B.Q., Ashammakhi N., Li S. Application of lung microphysiological systems to COVID-19 modeling and drug discovery: A review. Bio-Des. Manuf. 2021;4:757&#x2013;775. doi: 10.1007/s42242-021-00136-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42242-021-00136-5</ArticleId><ArticleId IdType="pmc">PMC8213042</ArticleId><ArticleId IdType="pubmed">34178414</ArticleId></ArticleIdList></Reference><Reference><Citation>Strikoudis A., Cie&#x15b;lak A., Loffredo L., Chen Y.-W., Patel N., Saqi A., Lederer D.J., Snoeck H.-W. Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells. Cell Rep. 2019;27:3709&#x2013;3723.e5. doi: 10.1016/j.celrep.2019.05.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.05.077</ArticleId><ArticleId IdType="pmc">PMC6594401</ArticleId><ArticleId IdType="pubmed">31216486</ArticleId></ArticleIdList></Reference><Reference><Citation>Low L.A., Mummery C., Berridge B.R., Austin C.P., Tagle D.A. Organs-on-chips: Into the next decade. Nat. Rev. Drug Discov. 2021;20:345&#x2013;361. doi: 10.1038/s41573-020-0079-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0079-3</ArticleId><ArticleId IdType="pubmed">32913334</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch E.W., Bahinski A., Huh D. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 2015;14:248&#x2013;260. doi: 10.1038/nrd4539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4539</ArticleId><ArticleId IdType="pmc">PMC4826389</ArticleId><ArticleId IdType="pubmed">25792263</ArticleId></ArticleIdList></Reference><Reference><Citation>Si L., Bai H., Oh C.Y., Jin L., Prantil-Baun R., Ingber D.E. Clinically Relevant Influenza Virus Evolution Reconstituted in a Human Lung Airway-on-a-Chip. Microbiol. Spectr. 2021;9:e00257-21. doi: 10.1128/Spectrum.00257-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00257-21</ArticleId><ArticleId IdType="pmc">PMC8557867</ArticleId><ArticleId IdType="pubmed">34523991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang P., Luo R., Wang Y., Li Z., Guo Y., Yao Y., Li M., Tao T., Chen W., et al. Biomimetic Human Disease Model of SARS-CoV-2-Induced Lung Injury and Immune Responses on Organ Chip System. Adv. Sci. 2021;8:2002928. doi: 10.1002/advs.202002928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202002928</ArticleId><ArticleId IdType="pmc">PMC7646023</ArticleId><ArticleId IdType="pubmed">33173719</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker V.V., Sharma K., Dhar N., Mancini G., Sordet-Dessimoz J., McKinney J.D. Rapid Endotheliitis and Vascular Damage Characterize SARS-CoV-2 Infection in a Human Lung-on-chip Model. EMBO Rep. 2021;22:e52744. doi: 10.15252/embr.202152744.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202152744</ArticleId><ArticleId IdType="pmc">PMC8183417</ArticleId><ArticleId IdType="pubmed">33908688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Liu J., Wang X., Feng L., Wu J., Zhu X., Wen W., Gong X. Organ-on-a-chip: Recent breakthroughs and future prospects. BioMed. Eng. OnLine. 2020;19:9. doi: 10.1186/s12938-020-0752-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12938-020-0752-0</ArticleId><ArticleId IdType="pmc">PMC7017614</ArticleId><ArticleId IdType="pubmed">32050989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>